VYNE Therapeutics (VYNE) Short Interest Ratio & Short Volume $2.77 +0.07 (+2.59%) As of 01/21/2025 04:00 PM Eastern Add Compare Share Share Short Interest Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrends VYNE Therapeutics Short Interest DataVYNE Therapeutics (VYNE) has a short interest of 61,400 shares, representing 0.48% of the float (the number of shares available for trading by the public). This marks a -1.60% decrease in short interest from the previous month. The short interest ratio (days to cover) is 0.5, indicating that it would take 0.5 days of the average trading volume of 164,404 shares to cover all short positions.Current Short Interest61,400 sharesPrevious Short Interest62,400 sharesChange Vs. Previous Month-1.60%Dollar Volume Sold Short$205,690.00Short Interest Ratio0.5 Days to CoverLast Record DateDecember 31, 2024Outstanding Shares14,750,000 sharesFloat Size12,710,000 sharesShort Percent of Float0.48%Today's Trading Volume183,642 sharesAverage Trading Volume164,404 sharesToday's Volume Vs. Average112% Short Selling VYNE Therapeutics? Sign up to receive the latest short interest report for VYNE Therapeutics and its competitors with MarketBeat's FREE newsletter. Email Address Skip Charts & View Short Interest HistoryShort Interest ChartDays to Cover ChartShort Percent of Float ChartVYNE Short Interest Over TimeVYNE Days to Cover Over TimeVYNE Percentage of Float Shorted Over Time VYNE Therapeutics Short Interest History Export to ExcelReport DateTotal Shares Sold ShortDollar Volume Sold ShortChange from Previous ReportPercentage of Float ShortedDays to CoverPrice on Report Date 12/31/202461,400 shares $205,690.00 -1.6%0.5%0.5 $3.35 12/15/202462,400 shares $159,744.00 -3.0%0.5%0.7 $2.56 11/30/202464,300 shares $190,328.00 -37.1%0.5%0.8 $2.96 11/15/2024102,200 shares $275,940.00 +23.7%0.8%1.3 $2.70 10/31/202482,600 shares $224,672.00 +65.2%0.7%1.2 $2.72 10/15/202450,000 shares $100,000.00 -14.1%0.4%1 $2.00 9/30/202458,200 shares $109,416.00 +75.8%0.5%1.3 $1.88 9/15/202433,100 shares $60,904.00 -28.8%0.3%0.7 $1.84 8/31/202446,500 shares $84,630.00 -20.0%0.4%0.9 $1.82 8/15/202458,100 shares $108,066.00 -13.0%0.5%1.1 $1.86 Get the Latest News and Ratings for VYNE and Related StocksEnter your email address below to receive the latest news and analysts' ratings for VYNE Therapeutics and its competitors with MarketBeat's FREE daily newsletter. 7/31/202466,800 shares $126,920.00 +8.1%0.5%1.3 $1.90 7/15/202461,800 shares $139,050.00 +10.6%0.5%1.1 $2.25 6/30/202455,900 shares $110,123.00 -10.9%0.5%1 $1.97 6/15/202462,700 shares $144,210.00 +22.2%0.5%0.7 $2.30 5/31/202451,300 shares $130,302.00 -10.6%0.4%0.6 $2.54 5/15/202457,400 shares $160,720.00 -30.0%0.5%0.6 $2.80 4/30/202482,000 shares $206,640.00 -15.3%0.7%0.8 $2.52 4/15/202496,800 shares $248,776.00 +13.1%0.8%0.9 $2.57 3/31/202485,600 shares $262,792.00 +590.3%0.7%0.7 $3.07 3/15/202412,400 shares $24,924.00 -63.4%0.1%0.1 $2.01 2/29/202433,900 shares $75,597.00 -5.3%0.3%0.3 $2.23 2/15/202435,800 shares $77,328.00 -31.8%0.3%0.4 $2.16 1/31/202452,500 shares $89,775.00 -40.3%0.4%0.5 $1.71 1/15/202488,000 shares $181,280.00 No Change0.7%0.2 $2.06 12/31/202388,000 shares $205,040.00 +1,157.1%N/A0.2 $2.33 12/15/20237,000 shares $19,180.00 -94.4%0.1%0 $2.74 11/30/2023124,800 shares $413,088.00 -15.0%1.0%0.4 $3.31 11/15/2023146,800 shares $604,816.00 +150.9%1.2%0.4 $4.12 10/31/202358,500 shares $178,425.00 +11.6%1.9%0.2 $3.05 10/15/202352,400 shares $144,100.00 -7.6%1.7%3.3 $2.75 9/30/202356,700 shares $229,068.00 -8.1%1.8%3.5 $4.04 9/15/202361,700 shares $237,545.00 -0.2%2.0%4.1 $3.85 8/31/202361,800 shares $268,830.00 -19.7%2.0%3.7 $4.35 8/15/202377,000 shares $373,450.00 +13.1%2.4%3.7 $4.85 7/31/202368,100 shares $316,665.00 +3.8%2.2%2 $4.65 7/15/202365,600 shares $276,832.00 -6.0%2.1%0.7 $4.22 6/30/202369,800 shares $286,180.00 -5.6%2.2%0.1 $4.10 6/15/202373,900 shares $352,281.30 +13.7%2.4%0.1 $4.77 5/31/202365,000 shares $408,850.00 -29.3%2.1%0.1 $6.29 5/15/202391,900 shares $705,792.00 -55.6%2.9%0.1 $7.68Do this Before Elon’s Reveal on January 29th (Ad)Elon’s newest tech could pay you an extra $30,000 a year — while you sleep. It’s smaller than a quarter but designed to power a $9 trillion AI revolution. And I’ve identified a little-known supplier Elon is depending on to make it all happen.I urge you to watch this video now. 4/30/2023206,800 shares $1.09 million +119.1%6.6%0.3 $5.26 4/15/202394,400 shares $256,768.00 -3.9%3.0%0.1 $2.72 3/31/202398,200 shares $302,456.00 +30.2%3.1%1.7 $3.08 3/15/202375,400 shares $192,270.00 +38.1%2.3%1 $2.55 2/28/202354,600 shares $182,091.00 -2.5%1.7%0.8 $3.34 2/15/202356,000 shares $196,560.00 -94.6%1.8%0.8 $3.51 1/31/20231,030,000 shares $267,800.00 -29.0%N/A0.8 $0.26 1/15/20231,450,000 shares $388,311.45 +105.2%N/A1.2 $0.27 12/30/2022706,800 shares $106,020.00 -7.4%N/A0.6 $0.15 12/15/2022763,400 shares $129,472.64 -4.3%N/A3.5 $0.17 11/30/2022797,700 shares $185,545.02 +3.5%N/A4.3 $0.23 11/15/2022770,600 shares $189,297.89 -3.6%N/A4.3 $0.25 10/31/2022799,300 shares $204,301.08 +3.2%N/A2.7 $0.26 10/15/2022774,400 shares $187,792.00 +0.0%N/A2.6 $0.24 9/30/2022774,200 shares $172,724.02 -22.4%N/A2.6 $0.22 9/15/2022997,900 shares $282,405.70 +48.9%N/A3.1 $0.28 8/31/2022670,200 shares $209,973.66 -6.0%N/A1.9 $0.31 8/15/2022713,200 shares $228,224.00 -4.9%N/A1.9 $0.32 7/31/2022750,300 shares $324,204.63 -15.5%N/A2.5 $0.43 7/15/2022887,400 shares $399,330.00 -22.8%N/A2.6 $0.45 6/30/20221,150,000 shares $447,350.00 -9.5%N/A2 $0.39 6/15/20221,270,000 shares $660,400.00 +5.0%N/A2 $0.52 5/31/20221,210,000 shares $492,954.00 -11.7%N/A1.8 $0.41 5/15/20221,370,000 shares $545,260.00 -12.7%N/A2 $0.40 4/30/20221,570,000 shares $659,400.00 +8.3%N/A2.1 $0.42 4/15/20221,450,000 shares $767,050.00 +57.0%N/A1.7 $0.53 3/31/2022923,800 shares $600,562.38 -19.0%N/A0.8 $0.65 3/15/20221,140,000 shares $638,400.00 -22.5%N/A1 $0.56 2/28/20221,470,000 shares $796,740.00 -6.4%N/A0.5 $0.54 2/15/20221,570,000 shares $893,487.00 -23.4%N/A0.6 $0.57 1/31/20222,050,000 shares $1.27 million +12.6%N/A0.7 $0.62 1/15/20221,820,000 shares $1.25 million -12.5%N/A0.7 $0.69 12/31/20212,080,000 shares $2.12 million -34.0%N/A0.9 $1.02 12/15/20213,150,000 shares $3.59 million +283.4%N/A1.3 $1.14 11/30/2021821,600 shares $846,248.00 -11.7%N/A0.6 $1.03 11/15/2021930,900 shares $1.19 million +5.5%N/A1.3 $1.28 10/29/2021882,000 shares $1.18 million +1.5%1.7%1 $1.34 10/15/2021869,400 shares $1.06 million -9.6%1.7%1 $1.22 9/30/2021962,100 shares $1.34 million -23.0%1.9%1.3 $1.39 9/15/20211,250,000 shares $1.85 million -11.4%2.5%1.5 $1.48 8/31/20211,410,000 shares $2.40 million -50.4%2.8%1.6 $1.70 8/13/20212,840,000 shares $5.06 million -6.6%5.6%3.2 $1.78 7/30/20213,040,000 shares $8.21 million +7.8%6.0%4.1 $2.70 7/15/20212,820,000 shares $7.76 million +9.7%5.6%3.2 $2.75 6/30/20212,570,000 shares $9.02 million -35.6%5.1%2.8 $3.51 6/15/20213,990,000 shares $14.52 million -1.2%7.9%4.6 $3.64 5/28/20214,040,000 shares $15.96 million -7.3%8.0%4.6 $3.95 5/14/20214,360,000 shares $14.13 million +15.7%8.6%4.4 $3.24 4/30/20213,770,000 shares $19.34 million +13.2%7.5%2.5 $5.13 4/15/20213,330,000 shares $18.78 million -0.9%6.6%1.4 $5.64Do this Before Elon’s Reveal on January 29th (Ad)Elon’s newest tech could pay you an extra $30,000 a year — while you sleep. It’s smaller than a quarter but designed to power a $9 trillion AI revolution. And I’ve identified a little-known supplier Elon is depending on to make it all happen.I urge you to watch this video now. 3/31/20213,360,000 shares $22.14 million +14.7%6.7%1.4 $6.59 3/15/20212,930,000 shares $21.65 million +7.7%5.8%1.3 $7.39 2/26/20212,720,000 shares $21.46 million -71.8%5.4%1.2 $7.89 2/12/20219,660,000 shares $102.78 million -7.9%19.7%4.8 $10.64 1/29/202110,490,000 shares $93.57 million +15.2%5.8%1.6 $8.92 1/15/20219,110,000 shares $60.13 million No Change5.7%2.4 $6.60 8/14/20209,960,000 shares $64.14 million -3.7%N/A2.2 $6.44 7/31/202010,340,000 shares $66.59 million +19.0%N/A2.1 $6.44 7/15/20208,690,000 shares $56.31 million -22.7%N/A1.7 $6.48 6/30/202011,240,000 shares $81.38 million +62.0%N/A2.1 $7.24 6/15/20206,940,000 shares $61.07 million +44.9%N/A1.4 $8.80 5/29/20204,790,000 shares $45.79 million +20.1%N/A1.2 $9.56 5/15/20203,990,000 shares $26.97 million -29.6%N/A1.4 $6.76 4/30/20205,670,000 shares $41.28 million +9.7%N/A2.8 $7.28 4/15/20205,170,000 shares $28.75 million +106.0%N/A3.7 $5.56 3/31/20202,510,000 shares $26.91 million -5.0%N/A2.7 $10.72 3/13/20202,643,000 shares $31.93 million +389.2%18.5%2.6 $12.08 2/28/2020540,300 shares $6.38 million +4.8%3.8%1.5 $11.80 2/14/2020515,500 shares $10.45 million +3.3%3.6%2.6 $20.28 1/31/2020499,200 shares $9.19 million -11.6%4.3%3.1 $18.40 VYNE Short Interest - Frequently Asked Questions What is VYNE Therapeutics' current short interest? Short interest is the volume of VYNE Therapeutics shares that have been sold short but have not yet been covered or closed out. As of December 31st, investors have sold 61,400 shares of VYNE short. 0.48% of VYNE Therapeutics' shares are currently sold short. Learn More on VYNE Therapeutics' current short interest. What is a good short interest percentage for VYNE Therapeutics? Companies that have a short interest as a percentage of float below 10% indicates positive investor sentiment and few short sellers. Stocks with a short interest percentage above 10% is considered high, suggesting some investors are pessimistic about the stock. Companies with a short interest percentage of 20% or more indicates widespread negative sentiment. 0.48% of VYNE Therapeutics' floating shares are currently sold short. Is VYNE Therapeutics' short interest increasing or decreasing? VYNE Therapeutics saw a decline in short interest in December. As of December 31st, there was short interest totaling 61,400 shares, a decline of 1.6% from the previous total of 62,400 shares. Changes in short volume can be used to identify positive and negative investor sentiment. Investors that short sell a stock are betting that its price will decline in the future. An increase in short sale volume suggests bearish (negative) sentiment among investors. A decrease on short sale volume suggests bullish (positive) sentiment. What is VYNE Therapeutics' float size? VYNE Therapeutics currently has issued a total of 14,750,000 shares. Some of VYNE Therapeutics' outstanding shares are available for trading, while others are subject to various restrictions. The public float, also referred to as floating shares or "the float", are shares that publicly owned, unrestricted and available to trade on the open market. VYNE Therapeutics currently has a public float of 12,710,000 shares. How does VYNE Therapeutics' short interest compare to its competitors? 0.48% of VYNE Therapeutics' shares are currently sold short. Here is how the short interest of companies in the industry of "pharmaceutical products" compare to VYNE Therapeutics: Cybin Inc. (3.51%), Compugen Ltd. (1.42%), Cardiff Oncology, Inc. (18.60%), Aclaris Therapeutics, Inc. (4.98%), Silence Therapeutics plc (3.29%), scPharmaceuticals Inc. (12.91%), Alector, Inc. (6.84%), Lyell Immunopharma, Inc. (8.53%), Genfit S.A. (0.13%), Acrivon Therapeutics, Inc. (5.37%), Which stocks are the most shorted right now? As of the most recent reporting period, the following stocks had the largest short interest positions: AppLovin Co. ($5.83 billion), Charter Communications, Inc. ($3.77 billion), Reddit, Inc. ($2.98 billion), The Kroger Co. ($2.97 billion), International Paper ($2.64 billion), SoFi Technologies, Inc. ($1.99 billion), Rivian Automotive, Inc. ($1.93 billion), Onsemi ($1.81 billion), SoundHound AI, Inc. ($1.59 billion), and Moderna, Inc. ($1.57 billion). View all of the most shorted stocks. What does it mean to sell short VYNE Therapeutics stock? Short selling VYNE is an investing strategy that aims to generate trading profit from VYNE Therapeutics as its price is falling. VYNE shares are trading up $0.07 today. To short a stock, an investor borrows shares, sells them and buys the shares back on the public market later to return it to the lender. Short sellers are betting that a stock will decline in price. If the stock does drop after selling, the short seller buys it back at a lower price and returns it to the lender. The difference between the sell price and the buy price is the trader's profit. How does a short squeeze work against VYNE Therapeutics? A short squeeze for VYNE Therapeutics occurs when it has a large amount of short interest and its stock increases in price. This forces short sellers to cover their short interest positions by buying actual shares of VYNE, which in turn drives the price of the stock up even further. How often is VYNE Therapeutics' short interest reported? Short interest is typically published by a stock exchange once per month. However, NASDAQ publishes a report for U.S. stocks, including VYNE, twice per month. The most recent reporting period available is December, 31 2024. More Short Interest Resources from MarketBeat Related Companies Cybin Short Interest Data Compugen Short Interest Data Cardiff Oncology Short Interest Data Aclaris Therapeutics Short Interest Data Silence Therapeutics Short Interest Data scPharmaceuticals Short Interest Data Alector Short Interest Data Lyell Immunopharma Short Interest Data Genfit Short Interest Data Acrivon Therapeutics Short Interest Data Short Interest Tools Stocks to Short Largest Short Interest Positions Short Interest Increases Short Interest Decreases Short Interest Reporting Dates This page (NASDAQ:VYNE) was last updated on 1/22/2025 by MarketBeat.com Staff From Our PartnersBill Gates’ is about to mint millionaires (again) with Stargate.This little-known project that Bill Gates has been quietly working on that’s about to unleash an AI breakthrou...Brownstone Research | SponsoredDid You See Trump’s Manhattan Project Bombshell?This secret document contains stunning details about Donald Trump’s very first order of business… the minute h...Banyan Hill Publishing | SponsoredTrump currency shock imminentTrump's Quiet $1.9 Trillion Move Against the Fed A small army of Americans, with Trump's support, has launc...Stansberry Research | SponsoredJanuary 29th - the next big trading catalyst to watch Mark your calendar for January 29th. Because on that day, I believe we could see a $2 Trillion shock INTO t...Timothy Sykes | SponsoredElon’s #1 AI Stock” SET TO SOARForget ChatGPT! Because Elon Musk's AI promises to be 100x more powerful.Behind the Markets | SponsoredI was wrong. Dead wrong. I thought what happened 25 years ago was a once- in-a-lifetime event… but how wrong I was. Because here we...Porter & Company | SponsoredURGENT: This Altcoin Opportunity Won’t Wait – Act NowCrypto has officially entered the "banana zone" – that wild phase where prices can 1000x in days. It happen...Crypto Swap Profits | SponsoredNvidia’s Bold Move: Tackling Tech’s $1 Trillion CrisisTaiwan Semiconductor, a partner of Nvidia’s for more than two decades, has seen its shares explode as much as ...Weiss Ratings | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding VYNE Therapeutics Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share VYNE Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free VYNE Stock Alerts